These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11249042)

  • 1. Generalised seizures following ondansetron.
    Sharma A; Raina V
    Ann Oncol; 2001 Jan; 12(1):131-2. PubMed ID: 11249042
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
    du Bois A; Vach W; Holy R; Kriesinger-Schröder H
    Support Care Cancer; 1996 Sep; 4(5):384-9. PubMed ID: 8883233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaphylactic reaction to ondansetron.
    Weiss KS
    Arch Intern Med; 2001 Oct; 161(18):2263. PubMed ID: 11575988
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
    Ishida T; Kusaba T; Hayakawa H
    Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
    Marschner NW; Adler M; Jaenicke F; Albrecht U; Nagel GA
    Onkologie; 1990 Aug; 13(4):313-5. PubMed ID: 2146577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
    Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
    Gilbert CJ; Petros WP; Vredenburgh J; Hussein A; Ross M; Rubin P; Fehdrau R; Cavanaugh C; Berry D; McKinstry C; Peters WP
    Cancer Chemother Pharmacol; 1998; 42(6):497-503. PubMed ID: 9788577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron-induced dystonia, hypoglycemia, and seizures in a child.
    Patel A; Mittal S; Manchanda S; Puliyel JM
    Ann Pharmacother; 2011 Jan; 45(1):e7. PubMed ID: 21189365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
    Hebbar M; Hecquet B; Vanlemmens L; Lecomte S; Pion JM; Adenis A; Bonneterre J
    Bull Cancer; 1995 Jan; 82(1):67-9. PubMed ID: 7742620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group.
    Beck TM; York M; Chang A; Navari R; Harvey WH; Meshad M; Griffin D; Wentz A
    Cancer Invest; 1997; 15(4):297-303. PubMed ID: 9246149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
    Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
    Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.